A study of the effects GAP-486 [rotigaptide] on ventricular tachyarrhythmia induction.

Trial Profile

A study of the effects GAP-486 [rotigaptide] on ventricular tachyarrhythmia induction.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Rotigaptide (Primary)
  • Indications Arrhythmias
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2007 The expected completion date for this trial is now 1 Oct 2006.
    • 07 Nov 2006 Status change
    • 16 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top